tolvaptan has been researched along with Nephrotic Syndrome in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagga, A; Hari, P; Meena, J; Sinha, A | 1 |
| Delbet, JD; Parmentier, C; Ulinski, T | 1 |
| Kaku, Y; Nishimura, M; Saimiya, M | 1 |
| Hoshiyama, A; Kamata, Y; Masaki, T; Shichiri, M; Takada, T; Toki, T | 1 |
| Ishikawa, S; Iwasaki, H; Kuroda, M; Muraoka, M; Ohta, K; Shimizu, M; Tasaki, Y; Yachi, Y; Yachie, A | 1 |
| Bockenhauer, D | 1 |
| Amaha, M; Matsumura, D; Nakamura, T; Nomura, M; Ono, Y; Sato, E; Ueda, Y; Yamagishi, H | 1 |
| Imamura, T | 1 |
| Nakamura, T; Node, K; Sato, E; Tanaka, A | 1 |
| Nakamura, T; Node, K; Sato, E; Tanaka, A; Ueda, Y | 1 |
10 other study(ies) available for tolvaptan and Nephrotic Syndrome
| Article | Year |
|---|---|
Efficacy and Safety of Combination Therapy with Tolvaptan and Furosemide in Children with Nephrotic Syndrome and Refractory Edema: A Prospective Interventional Study.
Topics: Child; Child, Preschool; Diuretics; Drug Therapy, Combination; Edema; Furosemide; Heart Failure; Humans; Male; Nephrotic Syndrome; Prospective Studies; Tolvaptan | 2022 |
Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome.
Topics: Antidiuretic Hormone Receptor Antagonists; Female; Humans; Hyponatremia; Infant; Nephrotic Syndrome; Tolvaptan | 2020 |
Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.
Topics: Antidiuretic Hormone Receptor Antagonists; Child; Edema; Humans; Hyponatremia; Male; Nephrotic Syndrome; Tolvaptan | 2021 |
Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diabetic Nephropathies; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Nephrotic Syndrome; Renal Insufficiency; Severity of Illness Index; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance | 2018 |
Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.
Topics: Anti-Inflammatory Agents; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Child; Edema; Female; Humans; Nephrotic Syndrome; Prednisolone; Renal Dialysis; Tolvaptan; Urodynamics | 2014 |
Draining the edema: a new role for aquaretics?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diabetes Insipidus, Neurogenic; Edema; Female; Humans; Male; Nephrotic Syndrome; Tolvaptan | 2014 |
Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Diabetic Nephropathies; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Nephrotic Syndrome; Retrospective Studies; Tolvaptan | 2014 |
Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Diabetic Nephropathies; Female; Humans; Male; Nephrotic Syndrome; Tolvaptan | 2014 |
Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Biomarkers; Diabetic Nephropathies; Female; Heart Failure; Humans; Nephrotic Syndrome; Tolvaptan; Treatment Outcome | 2016 |
Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diagnosis, Differential; Edema; Female; Glomerulonephritis, Membranous; Humans; Middle Aged; Nephrotic Syndrome; Tolvaptan | 2017 |